The ATLAS score calculator evaluates the risk of mortality associated with Clostridioides difficile infection by examining five patient-specific factors. These factors include the patient's age, whether they received systemic antibiotics during infection therapy, leukocyte count, serum albumin levels, and body temperature. Each characteristic contributes a score, which, when totaled, predicts the risk of mortality.

The scoring method assigns values based on the following criteria:

- Age:
  - Less than 60 years = 0
  - Between 60 and 79 years = 1
  - 80 years or older = 2

- Treatment with systemic antibiotics during the infection therapy:
  - No = 0
  - Yes = 2

- Leukocyte count (cells/mcL):
  - Less than 16,000 = 0
  - Between 16,000 and 25,000 = 1
  - Greater than 25,000 = 2

- Serum albumin:
  - Greater than 35 g/L = 0
  - Between 26 and 35 g/L = 1
  - 25 g/L or less = 2

- Temperature:
  - 37.5 degrees C or below = 0
  - Between 37.6 and 38.5 degrees C = 1
  - 38.6 degrees C or higher = 2

To determine the final ATLAS score, the values corresponding to each condition are summed. This summed value, which can range from 0 to 10, is used to estimate mortality risk:

- A total score of 2 or less signals a 0.0% risk of mortality.
- A score of 3 suggests a 3.6% risk.
- A score of 4 indicates a 4.2% risk.
- A score of 5 raises the risk to 8.7%.
- A score of 6 corresponds to a 10.9% risk.
- A score of 7 marks a 14.3% risk.
- A score of 8 predicts a substantial 56.0% risk.
- A score of 9 or higher implies a mortality risk exceeding 56.0%.

This calculated score aids healthcare providers in assessing the severity of a patient’s infection and in making informed decisions regarding treatment strategies for Clostridioides difficile infection.

The ATLAS score is a clinical calculator used for patients with Clostridioides difficile infection (CDI). The full name of this scoring system is "Antibiotic Treatment and Length of Stay" score. It is used to predict the length of hospital stay in patients with CDI, which can help in hospital resource planning and patient management. 

The ATLAS score takes into account several factors including age, comorbidities, leukocyte count, serum creatinine level, and the use of certain antibiotics. It is applicable to adult patients diagnosed with CDI. 

The clinical utility of the ATLAS score is to provide a risk stratification tool for healthcare providers to predict the length of hospital stay, which can be useful in guiding treatment decisions and discharge planning. 

There are no specific exclusion criteria for the use of the ATLAS score, but it may be less accurate in patients with atypical presentations of CDI or in those with other severe concurrent illnesses that could independently prolong hospital stay.

ATLAS score for Clostridioides difficile infection